sopharma

Public disclosure of inside information according to Article 17 of MAR

Preliminary sales revenue data for October 2026

Sofia, Bulgaria, November 20, 2026 – **"Sopharma" AD** (SFA: "Bulgarian Stock Exchange" AD, SPH: Warsaw Stock Exchange) pursuant to the requirements of art. 100t of the Law on Public Offering of Securities (LPOS), hereby informs that in October 2026 the Company reported a 45% decrease in sales compared to the same month of the previous year, including a 17% decrease in domestic sales and a 57% decrease in export sales.

For the period from the beginning of 2026 through the end of October, the Company reported a 19% increase in sales compared to the same period of the previous year, including a 8% decrease in domestic sales and an 36% increase in export sales.

Pelagia Viatcheva, Investor Relations Director

Information about Sopharma AD

Sopharma AD *is a leading Bulgarian pharmaceutical company with more than 90 years of experience in the development, manufacturing and marketing of pharmaceutical products. The Company operates in accordance with European Good Manufacturing Practice (GMP) standards and is among the largest public companies by market capitalization on the Bulgarian Stock Exchange.*

Sopharma's activities include the development, manufacturing and commercialization of medicinal products, active pharmaceutical ingredients and other health related products, scientific research and development in the fields of chemistry, pharmacy and phytochemistry, as well as the production of medical devices and cosmetic products.

Sopharma Group *is a vertically integrated healthcare group operating across the pharmaceutical value chain, including pharmaceutical manufacturing, wholesale distribution, retail pharmacy, hospital supplies and related healthcare services. Through its integrated business model, the Group serves patients and healthcare professionals across numerous markets in Central and Eastern Europe and other international markets.*